Research into immunisation has been based on the theory that the benefits of immunisation far outweigh the risks from delayed adverse events and so long term safety studies do not need to be performed. When looking at diabetes—only one potential chronic adverse event—we found that the rise in the prevalence of diabetes may more than offset the expected decline in long term complications of H influenzae meningitis. Thus diabetes induced by vaccine should not be considered a rare potential adverse event. The incidence of many other chronic immunological diseases, including asthma, allergies, and immune mediated cancers, has risen rapidly and may also be linked to immunisation.

We believe that the public should be fully informed that vaccines, though effective in preventing infections, may have long term adverse effects. An educated public will probably increasingly demand proper safety studies before widespread immunisation. We believe that the outcome of this decision will be the development of safer vaccine technology.

John Barthelow Classen, President*

Classen Immunotherapies, 6517 Montrose Avenue, Baltimore, MD 21212, USA ten.seniccav@nessalC
David C Classen, Infectious disease physician*

Division of Infectious Diseases, LDS Hospital, Salt Lake City, UT, USA
Source: BMJ. 1999 Jan 16; 318(7177): 193.

Add your comment or reply. Your email address will not be published. Required fields are marked *